Impact of Intermittent Preventive Treatment With Dihydroartemisinin-Piperaquine on Malaria in Ugandan Schoolchildren: A Randomized, Placebo-Controlled Trial

Joaniter I. Nankabirwa,1,2 Bonnie Wandera,3 Pauline Amuge,1 Noah Kiwanuka,3 Grant Dorsey,4 Philip J. Rosenthal,4 Simon J. Brooker,5,6 Sarah G. Staedke,2,5 and Moses R. Kamya1,2

1Department of Medicine, Makerere University College of Health Sciences, 2Infectious Disease Research Collaboration, and 3Department of Epidemiology and Biostatistics, School of Public Health, Makerere University College of Health Sciences, Kampala, Uganda; 4Department of Medicine, San Francisco General Hospital, University of California, San Francisco; 5Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, United Kingdom; and 6Malaria Public Health and Epidemiology Group, Kenya Medical Research Institute–Wellcome Trust Collaborative Programme, Nairobi, Kenya

Background. Intermittent preventive treatment (IPT) in schoolchildren offers a promising option for malaria control. However, the optimal drug and dosing regimens for IPT remain to be determined.

Methods. We conducted a randomized, double-blind, placebo-controlled trial in 740 schoolchildren aged 6–14 years living in a setting of high malaria transmission in Uganda. Enrolled children were randomized to dihydroartemisinin-piperaquine (DP) given once a month (IPTm), DP given once a school term (4 treatments over 12 months, IPTst), or placebo and followed for 12 months. The primary outcome was the incidence of malaria over 12 months. Secondary outcomes included parasite prevalence and anemia over 12 months. Analyses were conducted on an intention-to-treat basis.

Results. In the placebo arm, the incidence of malaria was 0.34 episodes per person-year and the prevalence of parasitemia and anemia was 38% and 20%, respectively. IPTm reduced the incidence of malaria by 96% (95% confidence interval [CI], 88%–99%, \( P < .0001 \)), the prevalence of asymptomatic parasitemia by 94% (95% CI, 92%–96%, \( P < .0001 \)), and the prevalence of anemia by 40% (95% CI, 19%–56%, \( P < .0001 \)). IPTst had no significant effect on the incidence of symptomatic malaria or the prevalence of anemia, but reduced the prevalence of asymptomatic parasitemia by 54% (95% CI, 47%–60%, \( P < .0001 \)).

Conclusions. Monthly IPT with DP offered remarkable protection against clinical malaria, parasitemia, and anemia in schoolchildren living in a high-malaria-transmission setting.

Clinical Trials Registration. NCT01231880.

Keywords. malaria; intermittent preventive treatment; schoolchildren.

Children of school age (5–14 years) benefit relatively little from current malaria control interventions, due to a focus on younger children and pregnant women [1, 2]. Yet, in Africa, 20%–50% of school-aged children experience malarial episodes each year [3], with a negative impact on school attendance and educational performance [4, 5]. In high-transmission settings, up to 70% of school-aged children harbor malaria parasites, causing anemia [6], cognitive impairment [7, 8], and maintenance of reservoirs that promote transmission to others. Clearly, malaria control would be a valuable addition to school health programs.

One intervention under investigation is intermittent preventive treatment (IPT), the administration of
curative doses of antimalarials at predefined intervals regardless of infection status. IPT targeted at schoolchildren has resulted in reduced rates of malaria, asymptomatic parasitemia, and anemia, as well as improved cognitive function [9–13]. However, the optimal drug and dosing regimen are uncertain. We previously showed that, in a region of high malaria transmission, a single 3-day course of dihydroartemisinin-piperaquine (DP) better prevented malarial parasitemia over 42 days and was better tolerated than either sulfadoxine-pyrimethamine (SP) or amodiaquine plus sulfadoxine-pyrimethamine (AQ + SP) [14]. We herein report results of a trial evaluating DP, either monthly (IPTm) or once per school term (IPTst), in schoolchildren in a high-malaria-transmission setting in Uganda.

METHODS

Study Design, Setting, and Population
This randomized, double-blind, placebo-controlled trial was conducted between February 2011 and February 2012 in Mulanda Primary School, Tororo District, in eastern Uganda. Tororo District is characterized by high-intensity year-round malaria transmission, principally of Plasmodium falciparum, with an estimated entomological inoculation rate of 562 infectious bites per person per year [15]. In the 5 years prior to this study, malaria control in Tororo District was typically limited to the promotion of IPT during pregnancy, distribution of insecticide-treated nets (ITNs) through antenatal care services, and malaria case management with artemisinin-based combination therapy. In January 2011, a community-based mass campaign to distribute free ITNs was conducted.

Mulanda subcounty has 8 primary schools. Mulanda Primary School was selected due to its large population (1320 students) and close proximity (approximately 500 m) to the main public health facility, Mulanda Health Centre IV. Meetings were held to explain the nature and purpose of the trial to teachers and parents or guardians, and written informed consent was obtained. All children with consent from their parent/guardian were screened for eligibility. Children were excluded if they had (i) known allergy or adverse reaction to artemisinin-based regimens; (ii) history of meningitis; (iii) fever (axillary temperature ≥37.5°C) or history of fever in the previous 24 hours; (iv) evidence of severe malaria or danger signs; or (v) ongoing antimalarial treatment. Recruitment was done once and closed after baseline assessments.

Enrollment Procedures
At enrollment, a standardized questionnaire was administered to children fulfilling selection criteria to obtain data on sociodemographics and bed-net ownership and use. A standardized assessment of symptoms and a focused physical examination including measurement of weight and temperature were conducted. A finger-prick blood sample was obtained to assess for Plasmodium infection by thick and thin blood smear and for hemoglobin estimation. A stool sample was collected to assess for helminth infection. All children received a long-lasting ITN, and a single dose of albendazole (400 mg) was administered.

Study Drugs and Treatment Allocation
A randomization list was computer-generated using fixed blocks of 12 by an individual not involved in patient care. Participants were randomized using previously prepared, consecutively numbered, opaque sealed envelopes and assigned study numbers sequentially. A nurse not involved in care allocated the study group after opening the correspondingly numbered envelope. All other study personnel were blinded to study group assignments, and children were not informed of their regimen, but the color and taste of study medication and placebo were dissimilar. Study drugs were dosed as DP (Duocotexin, Holley-Cotec Pharmaceuticals, Beijing, China) once daily for 3 consecutive days each month (IPTm), or at the beginning of each school term (February 2011, May 2011, August 2011, and January 2012 [IPTst]). DP was dosed using weight-based guidelines targeting a total dose of 6.4 mg/kg dihydroartemisinin and 51.2 mg/kg piperaquine, given with glucose biscuits. Placebo was administered to the placebo and IPTst groups to simulate the IPTm dosing schedule. All treatment was administered at school by the study nurses and was directly observed. After drug administration, children were observed for 30 minutes, and treatment was readministered if vomiting occurred.

Follow-up Visits
Finger-prick blood smears were performed monthly to assess for Plasmodium infection. At the start of each school term, standardized history and physical examination and assessments for hemoglobin were performed prior to treatment. Children absent for any scheduled visits were followed up at home. School attendance was assessed daily by roll call by teachers, with absent children followed up at home by study personnel to establish reasons for absenteeism. Children who were absent due to illness were taken to the study clinic for diagnosis, management, and documentation. Adverse events were assessed and graded according to standardized criteria. Children with illnesses other than malaria received standard of care or were referred to Mulanda Health Centre. Medications with antimalarial activity were avoided whenever possible.

Recording of Clinical Malaria Episodes
Monitoring for malaria was by active case detection. Sick children were identified by teachers and sent to the study clinic and absent children were visited at home and taken to the study clinic if ill. The clinic was open 7 days a week. Children with...
documented fever (axillary temperature ≥37.5°C) or history of fever in the previous 24 hours had a blood sample for thick and thin smears. Malaria was defined as fever (documented or by history) with any quantity of malaria parasites on the blood smear. Episodes of uncomplicated malaria were treated with artemether-lumefantrine, the recommended first-line treatment in Uganda, following standard dosing guidelines and under supervision of the study nurse. Treatment failures within 14 days of prior therapy were treated with oral quinine 10 mg/kg every 8 hours for 7 days. Episodes of complicated malaria (severe malaria or danger signs) were referred to Mulanda Health Centre IV for intravenous quinine.

**Laboratory Evaluations**

Blood smears were labeled, air dried, and stained with 2% Giemsa for 30 minutes. Parasite densities were determined from thick blood smears by counting asexual parasites per 200 white blood cells (or per 500 white blood cells if the count was <10 parasites per 200 cells), assuming a white blood cell count of 8000 cells/mL. A smear was considered negative if no parasites were seen in 100 high-powered fields. Gametocytemia was determined using the same methodology. Thin smears were viewed for species identification. Two independent and experienced microscopists read the slides, with a third microscopist resolving discrepancies. Stool examination was by the Kato-Katz technique to assess for helminth infections. Hemoglobin concentration was assessed using a portable hemoglobinometer (HemoCue Ltd, Angelholm, Sweden) and estimated to 0.1 g/dL. Follow-up for malaria, anemia, and parasitemia were conducted for 12 months after enrollment. Participants were withdrawn for change of school, withdrawal of informed consent, or noncompliance with study procedures.

**Statistical Analysis**

The study was designed to test the hypothesis that IPTm would reduce the incidence of malaria compared with placebo by 33% or greater. We assumed that the incidence of malaria would be 0.57 episodes per person year in the placebo arm [14], and thus we would need to enroll 228 participants in each arm to detect our targeted protective efficacy with 80% power at 95% significance, allowing for 10% loss to follow-up.

Data were double-entered and cross-checked in a bespoke Microsoft Access database (Microsoft Corp, Seattle, Washington). Consistency checks were performed and all discrepancies and queries verified against original paper forms. Statistical analyses were done using Stata version 12.0 software (StataCorp, College Station, Texas). All analyses used an intention-to-treat approach. Incidence outcomes were compared using a negative binomial regression model, and prevalence outcomes were compared using generalized estimating equations with adjustment for repeated measures in the same study participant. Measures of association were expressed as incidence rate ratios, prevalence ratios, and mean differences. A P value ≤.05 was considered statistically significant. The primary outcome was the incidence of malaria, defined as the number of incident episodes per time at risk. Time at risk was calculated from the day

---

**Figure 1.** Trial profile. Abbreviations: F/up, follow-up; IPTm, intermittent preventive treatment once a month; IPTst, intermittent preventive treatment once a school term.
following the initiation of study drugs to the last day of observation, minus 14 days after each episode of malaria, a standard approach. Malaria within 1 month of IPTst was defined as any episode in March, June, or September, within 2 months as any episode in April, July, or October, within 3 months as any episode in May, August, or November, and within 4 months as any episode in December.

Secondary outcomes included prevalence of parasitemia, defined as the number of positive smears divided by the total number of smears over 1 year. Parasitemia after IPTst was defined as described above for malaria. Anemia was defined as <11.5 g/dL for children aged 6–11 years and <12.0 g/dL for those aged 12–14 years [16].

An adverse event was defined as any untoward medical occurrence, irrespective of its suspected relationship to study medications. All events were graded by severity and relationship to study treatment [17]. The risk of experiencing an adverse event was estimated, and comparisons with placebo were made using $\chi^2$ tests.

**Role of the Funding Source and Ethical Approval**

The sponsors had no role in study design, data collection, data analysis, data interpretation, or writing the report. The corresponding author had full access to study data and final responsibility for submission of the manuscript. Ethical approval was obtained from the Uganda National Council for Science and Technology and the Makerere University School of Medicine Research and Ethics Committee.

**RESULTS**

**Study Subjects and Follow-up**

Between January and February 2011, 826 children were screened for eligibility, and 740 (89.6%) met inclusion criteria and were randomized to study arms (Figure 1). Baseline characteristics of participants were similar across the study arms (Table 1). A total of 713 (96.4%) children completed 1 year of follow-up. Among the children lost during follow-up, 20 changed schools, 3 withdrew (1 hypersensitivity reaction after follow-up). Among the children lost during follow-up, 20 (Table 1). A total of 713 (96.4%) children completed 1 year of follow-up. Among the children lost during follow-up, 20 changed schools, 3 withdrew (1 hypersensitivity reaction after follow-up). Among the children lost during follow-up, 20 changed schools, 3 withdrew (1 hypersensitivity reaction after follow-up).

**Efficacy Outcomes Following IPT**

There were 167 incident episodes of malaria over 12 months of follow-up (Table 2). The incidence of malaria was significantly lower in the IPTm armp compared with the placebo arm (0.01 vs 0.34 episodes per person per year, respectively), resulting in a 96% protective efficacy (incidence rate ratio [IRR], 0.04; 95% confidence interval [CI], .01–.12; $P < .0001$). Compared with the placebo arm, the overall incidence of malaria (Table 2) or the cumulative risk of developing at least 1 episode of malaria (Figure 2) over 1 year of follow-up was not significantly different in the IPTst arm. However, compared with the placebo arm, the incidence of malaria was significantly lower within the first and second months after IPTst administration, resulting in 66% (IRR, 0.34; 95% CI, 0.19–0.59; $P < .0001$) and 45% (IRR, 0.55; 95% CI, 0.30–0.99; $P = .037$) protective efficacies within 1 and 2 months of IPTst administration, respectively. Restricting the case definition of malaria to fever and $>2000$ parasites/µL of blood yielded similar results and comparisons (Table 2).

The prevalence of parasitemia, which was assessed monthly, was significantly lower in the IPTm (2%) and IPTst (18%) arms compared with the placebo (38%) arm, resulting in a 94% protective efficacy with IPTm (prevalence ratio [PR], 0.06; 95% CI, 0.40–0.98; $P < .001$) and 54% protective efficacy with IPTst (PR, 0.46; 95% CI, 0.40–0.53; $P < .001$) over 1 year of follow-up. Similar to what was observed with malarial incidence, the prevalence of parasitemia in the IPTst group increased with increasing

### Table 1. Baseline Characteristics of the Study Population by Treatment Group

| Characteristic | Placebo | IPTst | IPTm |
|----------------|---------|-------|------|
| No. of children | 248     | 248   | 244  |
| Sex, female, No. (%) | 129 (52.0) | 139 (56.1) | 126 (51.6) |
| Age at enrollment, y, mean (SD) | 9.8 (2.3) | 9.7 (2.2) | 9.9 (2.1) |
| Weight, kg, mean (SD) | 28.6 (8.4) | 28.4 (8.2) | 28.6 (8.2) |
| Hemoglobin, g/dL, mean (SD) | 11.7 (1.0) | 11.7 (1.1) | 11.6 (1.0) |
| Household owning at least 1 bed-net, No. (%) | 224 (90.3) | 218 (87.9) | 220 (90.2) |
| Bed-net use in last 24 h, No. (%) | 91 (36.7) | 87 (35.1) | 84 (34.4) |
| Asymptomatic parasitemia | | | |
| All Plasmodium species, No. (%) | 79 (31.9) | 73 (29.4) | 71 (29.1) |
| P. falciparum | 70 | 70 | 64 |
| P. malariae | 5 | 1 | 5 |
| P. vivax | 2 | 0 | 2 |
| P. ovale | 2 | 2 | 0 |
| Geometric mean parasite density per µL | 549 | 647 | 611 |
| Gametocyte presence, No. (%) | 9 (3.6) | 6 (2.4) | 7 (2.9) |
| Helminths present, No. (%) | 21 (8.5) | 13 (5.2) | 22 (9.0) |
| Socioeconomic group, quartiles, No., (%) | | | |
| Poorest | 67 (27.0) | 62 (25.0) | 67 (27.5) |
| Poor | 85 (34.3) | 82 (33.1) | 74 (30.3) |
| Less poor | 41 (16.5) | 36 (14.5) | 43 (17.6) |
| Least poor | 55 (22.2) | 68 (27.4) | 60 (24.6) |

Abbreviations: IPTm, intermittent preventive treatment once a month; IPTst, intermittent preventive treatment once a school term; SD, standard deviation.
Table 2. Clinical, Parasitological, and Hematological Outcomes by Treatment Group After 1 Year of Follow-up

| Outcome                        | Study Group | Placebo | IPTst | IPTm |
|------|-------------|---------|-------|------|
|      |             | Events  | PYAR  | Incidence | Events  | PYAR  | Incidence | IRR IPTst vs Placebo (95% CI) | Events  | PYAR  | Incidence | IRR IPTm vs Placebo (95% CI) |
| Clinical malaria                |             |         |       |         |         |       |           |                             |         |       |           |                             |
| All episodes                     |             | 83      | 242.7 | 0.34    | 81      | 238.1 | 0.34      | 1.00 (.68–1.47)            | 3       | 240.5 | 0.01      | 0.04 (.01–.12)               |
| Parasite density >2000/µL        |             | 49      | 242.7 | 0.20    | 63      | 238.1 | 0.26      | 1.32 (.82–2.14)            | 1       | 240.5 | 0.004     | 0.02 (.003–.15)              |
| Episodes within 1 mo of IPTst*    |             | 38      | 94.8  | 0.40    | 12      | 93.5  | 0.13      | 0.31 (.15–.63)             | 0       | 94.3  | 0.00      | 0                            |
| Episodes within 2 mo of IPTst*    |             | 22      | 56.5  | 0.39    | 14      | 56.5  | 0.25      | 0.62 (.29–1.32)            | 0       | 56.4  | 0.00      | 0                            |
| Episodes within 3 mo of IPTst*    |             | 21      | 57.1  | 0.37    | 38      | 55.4  | 0.69      | 1.96 (1.06–3.62)           | 2       | 56.4  | 0.04      | 0.09 (.02–.42)               |
| Episodes within 4 mo of IPTst*    |             | 2       | 34.2  | 0.06    | 17      | 32.8  | 0.52      | 9.37 (2.09–42.1)           | 1       | 33.5  | 0.03      | 0.51 (.05–5.72)              |
| Parasitemia                      |             |         |       |         |         |       |           |                             |         |       |           |                             |
| All events                       |             | 1037    | 2700  | 0.38    | 472     | 2644  | 0.18      | 0.46 (.40–.53)             | 58      | 2638  | 0.02      | 0.06 (.04–.08)               |
| Events within 1 mo of IPTst*      |             | 326     | 981   | 0.33    | 23      | 960   | 0.02      | 0.07 (.05–.11)             | 19      | 960   | 0.02      | 0.06 (.04–.10)               |
| Events within 2 mo of IPTst*      |             | 297     | 738   | 0.40    | 126     | 726   | 0.17      | 0.43 (.35–.53)             | 14      | 721   | 0.02      | 0.05 (.03–.09)               |
| Events within 3 mo of IPTst*      |             | 307     | 737   | 0.42    | 238     | 720   | 0.33      | 0.79 (.69–.92)             | 20      | 719   | 0.03      | 0.06 (.04–.11)               |
| Events within 4 mo of IPTst*      |             | 107     | 244   | 0.44    | 85      | 238   | 0.36      | 0.81 (.65–1.02)            | 5       | 238   | 0.02      | 0.05 (.02–.12)               |
| Anemia                           |             |         |       |         |         |       |           |                             |         |       |           |                             |
| All events                       |             | 148     | 736   | 0.20    | 125     | 716   | 0.17      | 0.86 (.66–1.13)            | 87      | 717   | 0.12      | 0.60 (.44–.81)               |
| Gametocytemia                    |             |         |       |         |         |       |           |                             |         |       |           |                             |
| All events                       |             | 129     | 2700  | 0.05    | 54      | 2644  | 0.02      | 0.43 (.31–.58)             | 11      | 2638  | 0.004     | 0.03 (.05–.16)               |

Abbreviations: CI, confidence interval; IPTm, intermittent preventive treatment once a month; IPTst, intermittent preventive treatment once a school term; IRR, incidence rate ratio; PYAR, person year at risk.

* IPTst was administered in February, May, and August 2011 as well as January 2012. Events within 1 month of IPTst occurred in March, June, and September 2011. Events within 2 months of IPTst occurred in April, July, and October 2011. Events within 3 months of IPTst occurred in May, August, and November 2011. Events within 4 months of IPTst occurred in December 2011.
duration after treatment. The prevalence of gametocytemia was significantly lower in the IPTm and IPTst groups compared with the placebo group (Table 2).

Mean hemoglobin increased between baseline and 1 year in all children. The mean increase in hemoglobin in the IPTst group did not differ from that in the placebo group (0.86 g/dL [interquartile range (IQR), −0.1 to 1.8] vs 0.79 g/dL [IQR, −0.1 to 1.7]; P = .638). In contrast, the mean increase in hemoglobin in children in the IPTm group was significantly greater than that in the placebo group (1.20 g/dL [IQR, 0.1–2.15] vs 0.79 g/dL IQR −0.1 to 1.7; P = .003). The overall prevalence of anemia was significantly lower in the IPTm arm (0.12) but not the IPTst arm (0.17), compared with the placebo arm (0.20), resulting in a 40% protective efficacy for IPTm (PR, 0.60; 95% CI, 0.44–0.81; P = .030) (Table 2). Only 2 children had hemoglobin levels <8 g/dL during the 1-year follow-up period. One child, diagnosed with acute lymphoblastic leukemia, had severe anemia (hemoglobin level, 3.4 g/dL).

Safety Outcomes

There was 1 death, due to acute lymphoblastic leukemia, in a 7-year-old randomized to IPTst. Fourteen serious adverse events were reported, 6 in the IPTm group, 5 in the IPTst group, and 3 in the placebo group. All serious adverse events were judged unlikely to be associated with treatment; the most commonly reported events were fractures. Mild events, such as fever, headache, nausea, vomiting, and diarrhea, which were commonly associated with malaria, were more frequent in the placebo group than the intervention arms (Table 3).

DISCUSSION

School-aged children suffer consequences of malaria but are generally neglected in malaria control strategies. One control strategy under investigation for schoolchildren is IPT. We previously showed that, in Ugandan schoolchildren, a single course of DP was more efficacious than either SP or AQ + SP in preventing parasitemia over the subsequent 6 weeks [14]. In this study, we compared 2 DP dosing regimens and placebo in the same high-malaria-transmission setting. IPTm was highly efficacious, reducing the incidence of malaria by 96%, the prevalence of parasitemia by 94%, and the prevalence of anemia by 40%. IPTst only provided protection against malaria within the first 2 months after drug administration and against parasitemia within the first 3 months after drug administration. Our results suggest that DP administered at monthly intervals, but not dosed once a term, is a remarkably effective measure for the prevention of malaria in schoolchildren living in a high-transmission setting.

For IPT, a drug should eliminate circulating parasites and persist at sufficient levels to prevent multiplication of parasites acquired between doses. In our study, IPTm was highly efficacious in reducing parasitemia and preventing malaria. These findings are consistent with the long half-life of piperaquine.

![Figure 2. Cumulative risk of malaria over 1 year of follow-up by treatment group. Abbreviations: IPTm, intermittent preventive treatment once a month; IPTst, intermittent preventive treatment once a school term.](https://academic.oup.com/cid/article-abstract/58/10/1404/2895920)
Kenya, where the protective effect of IPT with AQ + SP against anemia was 48% [9]. In the Kenyan study, parasite prevalence was 4.6% in children receiving IPTst, compared with 17.8% in our study. The explanation for differential impacts on parasitemia and anemia in the 2 studies may be differences in transmission intensities, the drugs used for IPT, or the socioeconomic status of study participants.

IPT with SP is recommended in pregnancy (IPTp) and in infants (IPTi) living in areas with moderate to high malaria transmission, whereas seasonal malaria chemoprevention (SMC) with monthly AQ + SP is recommended in children aged <5 years living in areas with highly seasonal malaria transmission in the Sahel subregion of Africa [23]. Although studies have demonstrated benefits of IPT and SMC with SP-containing regimens [9, 24, 25], widespread resistance to SP in Africa [26] may render these malaria control measures ineffective [14, 27]. DP may serve as a suitable alternative, especially for SMC, for which issues of tolerability to AQ + SP have also been raised [14]. However, before implementation, the efficacy, tolerability, and safety of DP for IPTp, IPTi, and SMC should be further evaluated.

Our results suggest that monthly administration of DP will have major benefits for schoolchildren living in areas with high malaria endemicity. However, some concerns regarding this approach need to be addressed. First, the feasibility of monthly administration of a 3-day treatment regimen may be questioned, but it is noteworthy that schools offer relatively

---

### Table 3. Risk of Adverse Events in All Participants Over 1 Year of Follow-up by Treatment Group, and Pairwise Comparisons With Placebo

| Event Description | Placebo (n = 248) | IPTst (n = 248) | IPTm (n = 244) |
|-------------------|------------------|----------------|----------------|
| Any adverse event | 92.7 (88.8–95.4) | 90.7 (86.5–93.7) | 88.9 (84.4–92.3) |
| AEs commonly related to DP | | | |
| Anorexia | 1.2 (4–3.5) | 1.2 (4–3.5) | 1.6 (6–1.1) |
| Nausea | 5.7 (3.4–9.3) | 3.2 (1.6–6.2) | 0.8 (2–1.9) |
| Vomiting | 11.3 (7.9–15.8) | 9.7 (6.6–14.0) | 3.7 (2–6.9) |
| Diarrhea | 15.7 (11.7–20.7) | 6.9 (4.3–10.7) | 8.2 (5.4–12.3) |
| Pruritus | 0.8 (2–2.9) | 1.2 (4–3.5) | 0.8 (2–1.9) |

Commonest AEs reported

- Cough: 72.9 (67.1–78.1) vs 66.5 (60.5–72.1) vs 70.1 (64.1–75.5)
- Headache: 55.7 (49.4–61.7) vs 50.0 (43.8–56.2) vs 38.5 (32.6–44.8)
- Fever: 44.7 (38.7–50.9) vs 38.3 (32.5–44.5) vs 25.0 (19.9–30.8)
- Abdominal pain: 29.8 (24.5–35.8) vs 29.0 (23.7–34.9) vs 22.5 (17.8–28.2)
- Flu: 33.9 (28.3–39.9) vs 29.0 (23.7–34.9) vs 39.8 (33.8–46.0)
- Wounds: 18.6 (14.2–23.9) vs 18.6 (14.2–23.8) vs 17.6 (13.4–22.9)
- Skin rash: 10.9 (7.6–15.4) vs 12.5 (8.9–17.2) vs 11.1 (7.7–15.6)
- Joint aches: 9.3 (6.3–13.5) vs 10.1 (6.9–14.5) vs 7.8 (5.0–11.8)
- Sore throat: 10.9 (7.6–15.4) vs 8.9 (5.9–13.1) vs 8.6 (5.7–12.8)
- Weakness: 8.8 (5.3–12.1) vs 4.8 (2.8–8.3) vs 4.9 (2.8–8.4)

For all AEs except pruritus, the percentage of events where IPTm had a significant effect compared with placebo and IPTst was 15.4% (P = .003), 8.3% (P = .001), and 14.0% (P = .001), respectively. For pruritus, the percentage of events where IPTm had a significant effect compared with placebo and IPTst was 17.8% (P = .001), 8.3% (P = .001), and 14.0% (P = .001), respectively.

### Abbreviations

- AE: adverse event
- CI: confidence interval
- DP: dihydroartemisinin-piperaquine
- IPTm: intermittent preventive treatment once a month
- IPTst: intermittent preventive treatment once a school term
- SAE: severe adverse event

*Reference group is placebo.*

---

[18]. Previous studies have shown that DP is highly efficacious for the treatment of malaria, with substantial posttreatment prophylactic efficacy in Africa [19, 20] and Asia [21]. In one study that considered less-frequent preventive dosing, monthly DP was more efficacious than a bimonthly regimen in preventing malaria in adults in Thailand [22]. Similarly, in our study, IPTm was more efficacious than IPTst. Taken together, available results suggest that a monthly dosing interval is most appropriate for IPT with DP [18, 22].

IPTm significantly improved hemoglobin levels and reduced the risk of anemia, probably due to effects against malaria. IPTst had no effect on anemia, in contrast to a previous study in Kenya, where the protective efficacy of IPTst with AQ + SP against anemia was 48% [9]. In the Kenyan study, parasite prevalence was 4.6% in children receiving IPTst, compared with 17.8% in our study. The explanation for differential impacts on parasitemia and anemia in the 2 studies may be differences in transmission intensities, the drugs used for IPT, or the socioeconomic status of study participants.
Conducted by a Wellcome Trust Senior Fellowship in Basic Biomedical Science supported by training grants from the Fogarty International Center of the Development Consortium (WT084289MA) and the Bill & Melinda Gates Foundation. J. I. N. drafted the original version of the manuscript. All authors participated in follow-up of patients. J. I. N., B. W., N. K., S. J. B., S. G. S., M. R. K., P. J. R., and F. L. blinded to the participants’ study arms. Considering our results in light of these concerns, further study of the feasibility, safety, and cost-effectiveness of IPT targeted at schoolchildren with DP in different transmission settings will be warranted, but nonetheless, implementation of this highly efficacious intervention in the near future is worthy of strong consideration.

Notes

Acknowledgments. We thank the study staff, the teachers, and the study participants.

Author contributions. J. I. N., S. G. S., S. J. B., and M. R. K. conceived of and designed the study. J. I. N., B. W., and P. A. supervised the enrollment and follow-up of patients. J. I. N., B. W., N. K., S. J. B., S. G. S., M. R. K., P. J. R., and G. D. assisted with verification, analysis, and interpretation of the data. J. I. N. drafted the original version of the manuscript. All authors participated in the writing of the manuscript, and read and approved the final manuscript.

Financial support. This work was supported by the Malaria Capacity Development Consortium (WT084289MA) and the Bill & Melinda Gates Foundation (51941). Laboratory and data management components were supported by training grants from the Fogarty International Center of the National Institutes of Health (TW007357 and TW008077). S. J. B. is supported by a Wellcome Trust Senior Fellowship in Basic Biomedical Science (098045), W. B. is a THRIIVE fellow supported by the Wellcome Trust (087540), and Holley-Cotec provided the dihydroartemisinin-piperaquine.

Potential conflicts of interest. All authors: No reported conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Noor AM, Kirui VC, Brooker SJ, Snow RW. The use of insecticide treated nets by age: implications for universal coverage in Africa. BMC Public Health 2009; 9:369.

2. Pullan RL, Bukirwa H, Staedke SG, Snow RW, Brooker S. Plasmodium infection and its risk factors in eastern Uganda. Malar J 2010; 9:2.

3. Clarke SE, Brooker S, Njagi JK, et al. Malaria morbidity among schoolchildren living in two areas of contrasting transmission in western Kenya. Am J Trop Med Hyg 2004; 71:732–8.

4. Brooker S, Guyatt H, Omonno J, Shretta R, Drake L, Ouma J. Situation analysis of malaria in school-aged children in Kenya—what can be done? Parasitol Today 2000; 16:183–6.

5. Fernando SD, Rodrigo C, Rajapakse S. The ‘hidden’ burden of malaria: cognitive impairment following infection. Malar J 2010; 9:366.

6. Brooker S, Akhwale W, Pullan R, et al. Epidemiology of plasmodium-helmint infection in Africa: populations at risk, potential impact on anaemia, and prospects for combining control. Am J Trop Med Hyg 2007; 77(6 suppl):88–98.

7. Al Serour AW, Grantham-McGregor SM, Greenwood B, Costello A. Impact of asymptomatic malaria parasitaemia on cognitive function and school achievement of schoolchildren in the Yemen Republic. Parasitology 2000; 121(pt 4):357–45.

8. Nankabiwa J, Wandera B, Kwanuwa N, Staedke SG, Kamya MR, Brooker SJ. Asymptomatic Plasmodium infection and cognition among primary schoolchildren in a high malaria transmission setting in Uganda. Am J Trop Med Hyg 2013; 88:1102–8.

9. Clarke SE, Jukes MC, Njagi JK, et al. Effect of intermittent preventive treatment of malaria on health and education in schoolchildren: a cluster-randomised, double-blind, placebo-controlled trial. Lancet 2008; 372:127–38.

10. Dicko A, Sagara I, Sissoko MS, et al. Impact of intermittent preventive treatment with sulphadoxine-pyrimethamine targeting the transmission season on the incidence of clinical malaria in children in Mali. Malar J 2008; 7:123.

11. Kweku M, Liu D, Adjuik M, et al. Seasonal intermittent preventive treatment for the prevention of anaemia and malaria in Ghanaian children: a randomized, placebo controlled trial. PLoS One 2008; 3.

12. Cisse B, Cairns M, Faye E, et al. Randomized trial of sulphadoxine-pyrimethamine or dihydroartemisinin for malaria intermittent preventive treatment in children. PLoS One 2009; 4.

13. Barger B, Maiga H, Traore OB, et al. Intermittent preventive treatment using artemisinin-based combination therapy reduces malaria morbidity among school-aged children in Mali. Trop Med Int Health 2009; 14:784–91.

14. Nankabiwa J, Cundill B, Clarke S, et al. Efficacy, safety, and tolerability of three regimens for prevention of malaria: a randomized, placebo-controlled trial in Ugandan schoolchildren. PLoS One 2010; 5: e13438.

15. Okello PE, Van Bortel W, Byaruhanga AM, et al. Variation in malaria transmission intensity in seven sites throughout Uganda. Am J Trop Med Hyg 2006; 75:219–25.

16. World Health Organization. Iron deficiency anaemia: assessment, prevention and control. A guide for programme managers. Geneva, Switzerland: WHO, 2001.

17. Staedke SG, Jaghanathan P, Yeka A, et al. Monitoring antimalarial safety and efficacy anaemia: assessment, prevention and control. A case study from Uganda. Malar J 2008; 7:107.

18. Tarning J, Ashley EA, Lindegardh N, et al. Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand. Antimicrob Agents Chemother 2008; 52:1052–61.

19. Kamya MR, Yeka A, Bukirwa H, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial. PLoS Clin Trials 2007; 2:e20.

20. Yeka A, Dorsey G, Kamya MR, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. PLoS One 2008; 3:e2390.

21. Smithuis F, Kyaw MK, Phe O, et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated malaria in Uganda. Plasmodium falciparum infection and cognitive impairment following infection. Malar J 2010; 9:366.
falciparum malaria: an open-label randomised trial. Lancet Infect Dis 2010; 10:673–81.
22. Lwin KM, Phyo AP, Tarning J, et al. Randomized, double-blind, placebo-controlled trial of monthly versus bimonthly dihydroartemisinin-piperaquine chemoprevention in adults at high risk of malaria. Antimicrob Agents Chemother 2012; 56:1571–7.
23. World Health Organization. Seasonal malaria chemoprevention (SMC) for Plasmodium falciparum malaria control in highly seasonal transmission areas of the Sahel sub-regions in Africa. Geneva, Switzerland: WHO Global Malaria Programme, 2012.
24. Gosling RD, Gesase S, Mosha JF, et al. Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 374:1521–32.
25. Aponte JJ, Schellenberg D, Egan A, et al. Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials. Lancet 2009; 374:1533–42.
26. Iriemenam NC, Shah M, Gatei W, et al. Temporal trends of sulphadoxine-pyrimethamine (SP) drug-resistance molecular markers in Plasmodium falciparum parasites from pregnant women in western Kenya. Malar J 2012; 11:134.
27. Harrington WE, Mutabingwa TK, Muehlenbachs A, et al. Competitive facilitation of drug-resistant Plasmodium falciparum malaria parasites in pregnant women who receive preventive treatment. Proc Natl Acad Sci U S A 2009; 106:9027–32.
28. Greenwood B. The use of anti-malarial drugs to prevent malaria in the population of malaria-endemic areas. Am J Trop Med Hyg 2004; 70:1–7.
29. Davis TM, Hung TY, Sim IK, Karunajeewa HA, llett KF. Piperaquine: a resurgent antimalarial drug. Drugs 2005; 65:75–87.
30. Conrad DM, LeClair N, Arinaitwe E, et al. Comparative impacts over 5 years of artemisinin-based combination therapies on P. falciparum polymorphisms that modulate drug sensitivity in Ugandan children [Epub ahead of print]. J Infect Dis 2014.
31. Some AF, Sere YY, Dokomajilar C, et al. Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso. Antimicrob Agents Chemother 2010; 54: 1949–54.